NEW YORK (GenomeWeb News) – Sirius Genomics will work with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic markers for severe sepsis under a collaborative agreement, the company said today.
Sirius will work with the hospital system's Clinical Research and Development Department in a program aimed at developing a pharmacogenomic diagnostic to assess the responsiveness of severe sepsis patients to recombinant human activated Protein C, which is sold by Eli Lilly under the trade name Xigris.
"Access to AP-HP's severe sepsis patients will be critical in the validation of Sirius' sepsis biomarkers," Sirius President and CEO Brad Popovich said in a statement.
AP-HP is a public health system that includes 37 hospitals and undertakes an array of activities beyond healthcare, including research, health education, home nursing, teaching, and others.
Financial terms of the agreement were not disclosed.